This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of California, San Francisco (UCSF) provides $670,904 in funding from August 7, 2024 to July 31, 2029 to support research on developing a combination metabolic therapy for diffuse midline gliomas (DMGs), a type of devastating pediatric brain tumor.
The key products and services to be delivered under this award involve: 1) Determining whether combined inhibition of glucose-6-phosphate dehydrogenase (G6PD) and glyoxalase 1 (GLO1) can effectively abrogate DMG proliferation in preclinical models, and 2) Validating the use of deuterium-labeled glucose ([6,6'-2H]-glucose) as an imaging agent to provide an early readout of treatment response in DMG-bearing mice. This innovative research aims to identify and target critical metabolic vulnerabilities induced by the histone H3 (H3K27M) mutation driving DMG development, with the goal of translating these findings into improved therapeutic options and monitoring approaches for DMG patients.
Generated 3/25/25, 5:22 AM